Lexicon Pharmaceuticals | LXRX - Operating Expenses


Lexicon Pharmaceuticals reported $20.27M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Abbott USD 9.21B 17M Dec/2025
Acadia Pharmaceuticals USD 266.6M 23.72M Dec/2025
Agios Pharmaceuticals USD 141.54M 11.8M Dec/2025
Akebia Therapeutics USD 63.08M 8.26M Dec/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
AstraZeneca USD 12.53B 4.16B Dec/2025
BioMarin Pharmaceutical USD 676.18M 131.65M Dec/2025
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Esperion Therapeutics USD 83.21M 14.06M Dec/2025
Halozyme Therapeutics USD 211.07M 74.73M Dec/2025
Illumina USD 903M 69M Dec/2025
Insmed USD 513.55M 109.86M Dec/2025
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
J&J USD 17.44B 1.53B Mar/2026
Lexicon Pharmaceuticals USD 20.27M 6.1M Dec/2025
MacroGenics USD 53.32M 13.68M Dec/2025
MannKind USD 119.64M 56.29M Dec/2025
Merck USD 10.16B 558M Dec/2025
Moderna USD 1.54B 259M Dec/2025
Novartis USD 9.8B 61M Dec/2025
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Sarepta Therapeutics USD 853.02M 390.78M Dec/2025
Thermo Fisher Scientific USD 9.91B 867M Dec/2025
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
United Therapeutics USD 804.8M 5.79B Dec/2025
Vanda Pharmaceuticals USD 466M 20.33M Sep/2025